{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:49:41Z","timestamp":1789462181918,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hyperlipidemia (HLD) is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Nearly 30% of emergency department (ED) patients with chest pain have undiagnosed and\/or unmanaged HLD, putting them at an increased risk of ASCVD. Although safe and effective HLD treatments exist, the ED traditionally focuses on acute care and does not offer preventive cardiovascular care services. This represents a large, missed opportunity to improve cardiovascular health for the millions of Americans evaluated in the ED each year who are not receiving appropriate preventive care in the outpatient setting. The goals of this study are to determine the efficacy of novel ED-initiated preventive care on lowering cholesterol while also informing our understanding of patient adherence and implementation determinants of ED-initiated preventive cardiovascular care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will use a randomized, controlled, parallel-group trial of 130 ED patients being evaluated for acute coronary syndrome at a single site. Participants will be 40\u201375 years old with prior ASCVD, known diabetes, or 10-year ASCVD risk \u22657.5% who are not already receiving guideline-directed outpatient preventive care. Patients will be randomized with equal probability to EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) or usual care. Patients in the EMERALD arm will be started on a statin and referred for a 30-day follow-up with cardiology or primary care, depending on the 10-year ASCVD risk level. Usual care arm patients will not be prescribed a statin in the ED and will be asked to follow up with a primary care provider. The primary outcome will be a percent change in low-density lipoprotein cholesterol at 30 days. Secondary outcomes include percent change in low-density lipoprotein cholesterol at 180 days and nonhigh-density lipoprotein cholesterol at 30- and 180 days, the proportion of EMERALD patients who pick up their statin, and the proportion of patients who attend 30-day outpatient follow-up. We will also use mixed methods and semistructured interviews to identify patient adherence facilitators and barriers and implementation determinants for Emergency Medicine providers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This is the first study to evaluate a novel, protocolized ED-initiated preventive cardiovascular care approach for HLD. If successful, the EMERALD intervention may be able to improve the cardiovascular health for at-risk patients and serve as a use case for other modifiable cardiovascular disease risk factors, such as diabetes, hypertension, tobacco use, and obesity. This single-site study will inform a planned multisite trial.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000390","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:00:08Z","timestamp":1745845208000},"page":"e0390","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial"],"prefix":"10.1097","volume":"24","author":[{"given":"Nicklaus P.","family":"Ashburn","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Wake Forest University School of Medicine (WFUSM), Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Snavely","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Wake Forest University School of Medicine (WFUSM), Winston-Salem, NC"},{"name":"Department of Biostatistics and Data Science, WFUSM, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly R.","family":"Ehrig","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Wake Forest University School of Medicine (WFUSM), Winston-Salem, NC"},{"name":"Department of Biostatistics and Data Science, WFUSM, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Section on Cardiovascular Medicine, Department of Internal Medicine, WFUSM, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Herrington","sequence":"additional","affiliation":[{"name":"Section on Cardiovascular Medicine, Department of Internal Medicine, WFUSM, Winston-Salem, NC"},{"name":"Department of Epidemiology and Prevention, WFUSM, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Reboussin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, WFUSM, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina B.","family":"Gesell","sequence":"additional","affiliation":[{"name":"Department of Social Sciences and Health Policy, WFUSM, Winston-Salem, NC"},{"name":"Department of Implementation Science, WFUSM, Winston Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Mahler","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Wake Forest University School of Medicine (WFUSM), Winston-Salem, NC"},{"name":"Department of Epidemiology and Prevention, WFUSM, Winston-Salem, NC"},{"name":"Department of Implementation Science, WFUSM, Winston Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"R1-20250822","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association.","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"R2-20250822","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R3-20250822","doi-asserted-by":"crossref","first-page":"e208236","DOI":"10.1001\/jamanetworkopen.2020.8236","article-title":"Estimation of atherosclerotic cardiovascular disease risk among patients in the Veterans Affairs health care system.","volume":"3","author":"Vassy","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R4-20250822","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"R5-20250822","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease.","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R6-20250822","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R7-20250822","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R8-20250822","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20250822","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease.","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"R10-20250822","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"R11-20250822","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"R12-20250822","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy.","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R13-20250822","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"R14-20250822","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease.","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"R15-20250822","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R16-20250822","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"R17-20250822","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R18-20250822","doi-asserted-by":"crossref","first-page":"e2986","DOI":"10.1371\/journal.pone.0002986","article-title":"Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian randomisation study.","volume":"3","author":"Linsel-Nitschke","year":"2008","journal-title":"PLoS One"},{"key":"R19-20250822","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease.","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"R20-20250822","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and Non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients.","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250822","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"key":"R22-20250822","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R23-20250822","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement.","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"R24-20250822","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1161\/CIRCULATIONAHA.118.036528","article-title":"Safely identifying emergency department patients with acute chest pain for early discharge.","volume":"138","author":"Mahler","year":"2018","journal-title":"Circulation"},{"key":"R25-20250822","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCOUTCOMES.114.001384","article-title":"The HEART pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge.","volume":"8","author":"Mahler","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R26-20250822","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1161\/CIRCULATIONAHA.120.049298","article-title":"Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort.","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"key":"R27-20250822","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annemergmed.2019.12.008","article-title":"Performance of novel high-sensitivity cardiac troponin I Assays for 0\/1-Hour and 0\/2- to 3-hour evaluations for acute myocardial infarction: results from the HIGH-US study.","volume":"76","author":"Nowak","year":"2020","journal-title":"Ann Emerg Med"},{"key":"R28-20250822","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF02598962","article-title":"Cholesterol screening in the emergency department.","volume":"6","author":"Burns","year":"1991","journal-title":"J Gen Intern Med"},{"key":"R29-20250822","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.ahj.2006.07.015","article-title":"Evaluation of dyslipidemia in the emergency department: impact of cholesterol testing on subsequent therapy.","volume":"152","author":"Blomkalns","year":"2006","journal-title":"Am Heart J"},{"key":"R30-20250822","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajem.2023.06.009","article-title":"Rarely tested or treated but highly prevalent: hypercholesterolemia in emergency department observation unit patients with chest pain.","volume":"71","author":"Ashburn","year":"2023","journal-title":"Am J Emerg Med"},{"key":"R31-20250822","first-page":"91","article-title":"Emergency department observation unit patients want evaluation and treatment for hypercholesterolemia: a health belief model study.","volume":"22","author":"Ashburn","year":"2023","journal-title":"Crit Pathw Cardiol"},{"key":"R32-20250822","first-page":"110","article-title":"Preventive cardiovascular care for hypercholesterolemia in US emergency departments: a national missed opportunity.","volume":"22","author":"Ashburn","year":"2023","journal-title":"Crit Pathw Cardiol"},{"issue":"25 Suppl 2","key":"R33-20250822","first-page":"S49","article-title":"ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Goff","year":"2013","journal-title":"Circulation"},{"key":"R34-20250822","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R35-20250822","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250822","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"R37-20250822","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0002-9149(01)02226-3","article-title":"Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.","volume":"89","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"R38-20250822","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas coronary atherosclerosis prevention study.","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"R39-20250822","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R40-20250822","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R42-20250822","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/eb-2017-102699","article-title":"Mixed methods research: expanding the evidence base.","volume":"20","author":"Shorten","year":"2017","journal-title":"Evid Based Nurs"},{"key":"R44-20250822","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors-an (updated) overview of systematic reviews.","volume":"8","author":"Gast","year":"2019","journal-title":"Syst Rev"},{"key":"R45-20250822","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s11606-021-06648-1","article-title":"An adaptable framework for factors contributing to medication adherence: results from a systematic review of 102 conceptual frameworks.","volume":"36","author":"Peh","year":"2021","journal-title":"J Gen Intern Med"},{"key":"R46-20250822","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13012-016-0534-z","article-title":"Combined use of the Consolidated Framework for Implementation Research (CFIR) and the Theoretical Domains Framework (TDF): a systematic review.","volume":"12","author":"Birken","year":"2017","journal-title":"Implement Sci"},{"key":"R47-20250822","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"R48-20250822","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/qshc.2004.011155","article-title":"Making psychological theory useful for implementing evidence based practice: a consensus approach.","volume":"14","author":"Michie","year":"2005","journal-title":"Qual Saf Health Care"},{"key":"R49-20250822","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.321.7259.504","article-title":"Statistics notes: blinding in clinical trials and other studies.","volume":"321","author":"Day","year":"2000","journal-title":"BMJ"},{"key":"R51-20250822","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","article-title":"Purposeful sampling for qualitative data collection and analysis in mixed method implementation research.","volume":"42","author":"Palinkas","year":"2015","journal-title":"Adm Policy Ment Health"},{"key":"R52-20250822","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations.","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"R53-20250822","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association.","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T14:00:29Z","timestamp":1755871229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000390","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}